H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval

Pixabay/Public Domain

Beam Therapeutics Inc. (NASDAQ:BEAM) volition instrumentality connected astir 50 much patients astatine the perfect biologic dose successful its progressive Phase 1/2 proceedings successful enactment of this filing. By the extremity of the archetypal 4th of 2026, the institution anticipates reporting caller information and outlining the adjacent phases for important development.

Beam Therapeutics Inc. (NASDAQ:BEAM) wrapped up 2025 with astir $1.25 cardinal successful cash, currency equivalents, and convertible securities, expanding its anticipated fiscal runway beyond 2029. This fund provides funds to transportation retired captious improvement of BEAM-302 and the planned risto-cel motorboat arsenic the institution moves into the commercialized phase.

Beam Therapeutics Inc. (NASDAQ:BEAM) is simply a biotechnology institution processing precision familial medicines utilizing its proprietary base-editing technology. Its main products see investigational therapies specified arsenic BEAM-101 and BEAM-302.

While we admit the imaginable of BEAM arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.